Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
| Autor: | Wang, Eunice S. 1, ∗, Montesinos, Pau 2, Minden, Mark D. 3, Lee, Je-Hwan 4, Heuser, Michael 5, Naoe, Tomoki 6, Chou, Wen-Chien 7, Laribi, Kamel 8, Esteve, Jordi 9, Altman, Jessica K. 10, Havelange, Violaine 11, Watson, Anne-Marie 12, Gambacorti-Passerini, Carlo 13, 14, Patkowska, Elzbieta 15, Liu, Shufang 16, Wu, Ruishan 16, Philipose, Nisha 16, Hill, Jason E. 16, Gill, Stanley C. 16, Rich, Elizabeth Shima 16, Tiu, Ramon V. 16 |
|---|---|
| Zdroj: | In Blood 27 October 2022 140(17):1845-1857 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|